tiprankstipranks
Trending News
More News >
Tanvex Biopharma Inc (TANVF)
OTHER OTC:TANVF
US Market

Tanvex Biopharma (TANVF) Financial Statements

Compare
6 Followers

Tanvex Biopharma Financial Overview

Tanvex Biopharma's market cap is currently $374.51M. The company's EPS TTM is $-0.052; its P/E ratio is ―; Tanvex Biopharma is scheduled to report earnings on March 4, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Dec 21Dec 20Dec 19Dec 18
Income Statement
Total Revenue
Gross Profit$ -19.35M$ 3.55M$ 143.00K$ 0.00$ 0.00
Operating Income$ -1.61B$ -1.60B$ -2.10B$ -2.33B$ -1.95B
EBITDA$ -1.30B$ -1.25B$ -1.87B$ -2.04B$ -1.75B
Net Income$ -1.64B$ -1.54B$ -2.10B$ -2.27B$ -1.89B
Balance Sheet
Cash & Short-Term Investments$ ―$ ―$ ―$ ―$ ―
Total Assets$ 3.42B$ 4.71B$ 4.37B$ 3.57B$ 4.48B
Total Debt$ 1.84B$ 1.76B$ 1.46B$ 342.74M$ 0.00
Net Debt$ 1.05B$ -463.95M$ -603.96M$ -2.08B$ -3.53B
Total Liabilities$ 2.03B$ 1.92B$ 1.75B$ 542.12M$ 263.92M
Stockholders' Equity$ ―$ ―$ ―$ ―$ ―
Cash Flow
Free Cash Flow$ -1.43B$ -1.42B$ -1.86B$ -1.99B$ -1.71B
Operating Cash Flow$ -1.33B$ -1.39B$ -1.79B$ -1.90B$ -1.61B
Investing Cash Flow
Financing Cash Flow
Currency in USD

Tanvex Biopharma Earnings and Revenue History

Tanvex Biopharma Debt to Assets

Tanvex Biopharma Cash Flow

Tanvex Biopharma Forecast EPS vs Actual EPS